Abstract
Introduction: Cost-benefit analyses have been used to evaluate new targeted therapies for cancer, often relying on complex models and extrapolation of overall survival beyond clinical trial follow-up. This exploratory analysis conducts a basic cost-benefit analysis of targeted therapies in mCRC, using a Spanish perspective, based on observed survival in clinical trials.